$GH: The Shield Tests Nobody Paid For, Until Now

The 60 second version

• Guardant Health ($GH) sells cancer blood tests in two lines: tumour profiling and recurrence monitoring for oncologists, and Shield, a colorectal cancer screen that primary care doctors order.
• The shift: cancer detection is moving from tissue and procedures to a blood draw, and screening adults 45 and older is the largest pool of patients still left untested.
• Shield sits at Liftoff on our curve. The constraint easing is commercial payer coverage for patients under 65, and covered lives go from about 70 million to about 90 million on November 15.
• The evidence: Shield went from about 16,000 to about 66,000 tests a quarter in one year. Medicare, Medicare Advantage and now UnitedHealth pay for it, and management raised the full year Shield guide to 270,000 to 285,000 tests.
• The next test is Q3 results on November 5, 2026. It is the first quarter with UnitedHealth coverage live and the first with Abbott’s rival test on the market.
• Any one of these breaks the thesis: fewer than 75,000 Shield tests in Q3, revenue per test under $700, or a cut to the Shield guide or the revenue guide.

In the second quarter of 2026 Guardant ran about 66,000 Shield tests and collected about $800 for each one, on average. A year earlier it ran about 16,000 and collected roughly $945. Volume quadrupled while the price per test went the wrong way, and the reason behind that is the most useful fact about the company today.

Most of the gap came from commercially insured patients whose plans did not yet cover the test. Guardant processed their blood anyway, booked little or nothing for them, and paid lab costs of about $410 a sample. In effect it was teaching primary care doctors a new ordering habit before it could send most of the bills.

Here is our thesis in one sentence. The payer gate for patients under 65 is opening now, with UnitedHealth from August and Carelon from November 15, and that should turn volume Guardant already runs into paid tests, lifting gross profit per Shield test from about $390 toward $600 while the oncology franchise carries the fixed costs.

The shares are about 13% below their high on fears about Abbott’s competing test. We think the fear is reasonable and aimed at the wrong number. Revenue per test settles the argument, and the first clean read comes in two weeks.

The shift

Precision oncology moved to blood in stages. Liquid biopsy for tumour profiling in advanced cancer is a mature, reimbursed market, and oncologists order it as routine. Monitoring for residual disease after surgery came next and is growing quickly. Screening healthy people is the last stage and the biggest, because the patient pool is every adult over 45 rather than every cancer patient.

Science was not what held screening back. Shield won FDA approval in 2024, and Medicare set an advanced diagnostic laboratory test rate of $1,495. The binding constraint was who would pay for patients under 65. Without commercial coverage and a guideline listing, a family doctor could order the test but had no good way to get a 52 year old patient reimbursed, so many simply did not order it.

Three things eased that in 2026. In May the American Cancer Society added blood based screening to its guideline, and that addition triggers coverage mandates in a number of states. UnitedHealth coverage took effect in August. Carelon coverage starts November 15, which takes Shield to roughly 90 million covered lives, about three quarters of eligible patients.

That timing matters for anyone holding the shares. The step from roughly 60% to 75% of eligible lives lands in the middle of the fourth quarter, so the full effect will not appear in reported numbers until early 2027.

The company

Guardant sells blood tests and the data they produce. Guardant360 and its FDA approved Liquid CDx version profile a tumour’s mutations so an oncologist can pick a drug. Reveal looks for traces of cancer after treatment. Shield screens average risk adults for colorectal cancer. A fourth line sells testing and data to drug companies running trials.

The oncology business pays the bills. In Q2 it ran about 104,000 tests, up 63%, and its revenue rose 38%. That cash funds a primary care push that looks nothing like the old business. Guardant now has more than 400 field sales reps, a health system team of over 30, and a joint promotion with $DGX Quest Diagnostics that puts Shield inside the electronic medical record where doctors place orders.

The founders, Helmy Eltoukhy and AmirAli Talasaz, have run the company together since it started, and their strategy has stayed the same throughout: build volume first and let the economics follow. Shield is the boldest version of that strategy so far.

One small detail from the filings caught our attention. The 0% convertible notes, $490.7 million of them, mature on November 15, 2027, exactly two years to the day after Carelon coverage begins. The coincidence means nothing, but it makes the calendar easy to remember: one date opens the commercial market and the matching date a year later is when the debt comes due. The other detail is the FDA approval of a higher throughput lab workflow, which management says should cut Shield’s cost per test by about 15% by the end of 2026. Few headlines carried it, yet it may matter as much as any payer contract.

Where it sits on our curve

We put Shield at Liftoff, and we judge that on Shield’s own record, separate from the oncology tests. The oncology tests are much further along. Shield has demonstration, paid deployment and repeat paid volume across several unrelated payers, so the furthest step on our evidence sequence is expansion. It has not yet produced cash on its own.

The commitment behind that step is real money from separate buyers. Traditional Medicare pays the ADLT rate. Medicare Advantage plans pay. UnitedHealth, the largest commercial insurer in the country, signed on, and Carelon followed. Those are separate decisions by separate payers, and each one involved its own clinical review.

The buyer threshold we care about sits in two numbers. Blended revenue per test needs to climb from about $800 back above $1,000, and lab cost needs to fall from about $410 toward $350. Hit both and gross profit per test rises from around $390 to more than $600. At 300,000 tests a year, that difference is worth roughly $60 million of gross profit a year, and the fixed sales cost does not grow with it.

Is this repeatable, or a launch surge? The honest answer is that the Q2 number alone cannot tell us. The pattern of payer decisions points to repeatable demand. Revenue per test over the next two quarters will confirm it or refute it.

The numbers and what the street expects

Revenue was $335.0 million in Q2 2026, up 44%, after $301.7 million in Q1, up 48%, according to the company’s July 30 results release and its first quarter 10Q. Growth is running well above 40% on a base of more than $1.2 billion. Few diagnostics companies have done that.

Shield is the part that moves. Screening revenue went from $14.8 million in Q2 2025 to $41.6 million in Q1 2026 and $52.9 million in Q2 2026. Tests went from about 16,000 to 44,000 to about 66,000, up 50% on the quarter. Revenue per test fell from about $945 to about $800 over the same stretch, and management linked that drop to the growing share of unpaid commercial patients ahead of coverage.

Margins held up despite the unpaid tests. Adjusted gross margin was 67% in Q2, against 66% a year earlier, and the full year guide is 64% to 65%. The GAAP net loss was $120.1 million and adjusted EBITDA was a loss of $55.9 million. Free cash flow was a loss of $69.5 million for the quarter.

The balance sheet is adequate, with one wrinkle. At June 30 Guardant held $1.053 billion of cash plus $114 million of restricted cash. It owes about $1.5 billion in convertible notes: the $490.7 million of 0% notes due November 2027, $600 million at 1.25% due 2031 and $402.5 million at 0% due 2033, the last issued in November 2025. Full year free cash burn is guided at $195 million to $205 million, down from $233 million in 2025, and management targets cash flow breakeven by the end of 2027.

Dilution has been real. Diluted weighted shares were 132.9 million in Q2 against 124.1 million a year earlier, an increase of 7.1%. Part of that likely relates to stock sold alongside the November 2025 convertible, but we could not confirm the size of that offering.

Now the forward view. Management raised 2026 revenue guidance on July 30 to $1.34 billion to $1.36 billion, growth of 36% to 38%. It lifted the Shield guide to 270,000 to 285,000 tests and $218 million to $230 million of revenue, up from 230,000 to 245,000 tests. It also raised the 2028 revenue target to $2.2 billion from $2.0 billion.

The street sits at the top of that range. Aggregator data from MarketBeat and Yahoo show Q3 consensus of about $350.6 million in revenue and a loss of about $0.75 a share, with Q4 near $369 million. Full year 2026 consensus is $1.36 billion. For 2027 the figure is $1.84 billion, with a high to low spread of $1.72 billion to $1.93 billion. We could not confirm the analyst count from a source we trust, so we leave it out.

Revisions are rising. Before the July raise, 2026 consensus was about $1.31 billion. The 2027 figure implies 35% growth, which fits a path to $2.2 billion in 2028 without asking for anything heroic.

Why it wins

Start with the bill. A payer pays per test: $1,495 from traditional Medicare, a negotiated and lower rate from commercial plans, and about $800 blended across everything in Q2. Each additional test brings about $410 of lab cost, falling toward $350, plus sample transport and billing. The 400 reps cost the same whether they sell 60,000 tests a quarter or 100,000.

That cost structure is why the coverage news matters so much. Guardant already pays the lab cost on tests it is barely paid for. When a UnitedHealth member’s test moves from unpaid to paid, almost all of the new revenue becomes gross profit, because the cost was already being spent.

Who keeps the benefit? For now, Guardant does. The question is whether competition and commercial negotiations push the price down to payers over time. UnitedHealth’s rate was still being negotiated when the company last spoke, and that is a genuine unknown.

Next, the base technology question. Cheaper sequencing helps Guardant directly because it cuts the cost of goods on every test. It also lowers the cost for a rival to enter. On balance we think the help to Guardant is larger, because a lower cost base matters most to the company already running the most tests, and Guardant’s advantage was never the sequencer.

The moat is distribution and paperwork, and we mean that as praise. Shield was first to market, with FDA approval in 2024, ADLT pricing, guideline listings from NCCN and the ACS, about 90 million covered lives and an approved lower cost workflow. On top of that sit a primary care sales force, Quest’s reach and EMR ordering. Each draw also adds to a dataset for real world adherence and future multicancer work, and Guardant presented adherence results at ACG on October 15. We saw only the summary of those results, so we give them little weight here.

Is any of that impossible to copy? No. It is slow and expensive to copy, though, and the oncology franchise means Guardant can keep paying for it while a rival is still building.

What could go wrong

The strongest bear case runs like this. Early Shield volume came from a backlog of Medicare patients who had avoided colonoscopy for years, pulled forward by a heavy launch push. The falling revenue per test was more than a timing gap. Guardant was buying growth with free tests. Then $ABT Abbott arrives with Freenome’s SimpleScreen, approved by the FDA on July 27, 2026 with 81% sensitivity, launching this autumn through what was the Exact Sciences primary care sales force. Those reps already call on the same doctors.

Under that view, Shield volume growth stalls, commercial plans use a second approved test to press for lower prices, and revenue per test stays below $800 for good. We take that seriously. A rival with established relationships in primary care is the most dangerous kind of rival for a company whose whole plan rests on primary care.

What separates the two stories is revenue per test. If price rises alongside volume as UnitedHealth and Carelon claims get paid, coverage is the constraint that is easing. If volume grows while price falls below $700, or growth on the quarter collapses after Abbott’s launch, the bear case is right and we should say so.

Financing comes next. Set aside the $490.7 million due November 2027 and roughly $560 million of cash is left, which covers about 11 quarters at the current burn of about $50 million a quarter. Breakeven is targeted for late 2027, about five quarters away. The company can reach the next test and the cash after it with the money it has, provided the burn keeps falling. We could not confirm whether the 2027 notes settle in cash or shares, and with the stock well above most likely conversion prices, that choice affects dilution.

One more risk deserves its own line.

The oncology franchise funds everything, and any reimbursement hit there would squeeze Shield’s runway faster than any competitor could.

The investment thesis

We think Shield is converting volume Guardant already runs into paid volume as commercial coverage switches on, and that this conversion supports today’s valuation without needing the upside case.

The chain holds together. The constraint is easing: guidelines in May, UnitedHealth in August, Carelon in November. Adoption is responding, with tests up more than fourfold in a year and the guide raised. Guardant keeps the value because its lab cost is mostly already spent and its sales cost is fixed. Financing leaves something worthwhile for each share, because the company can reach breakeven without new equity if burn follows guidance, although 7% dilution last year reminds us that this is a condition and not a certainty.

Now the price. At $162.59 the market value is about $21.7 billion. Add about $1.49 billion of convertible notes, subtract $1.05 billion of cash, and enterprise value comes to about $22.2 billion. That is 16 times the 2026 guide midpoint and 12 times 2027 consensus. By our rough math $NTRA Natera trades near 19 times its 2026 revenue, so Guardant already sits at a discount to the obvious comparable.

Our downside case assumes 2027 revenue of $1.70 billion as Shield stalls against Abbott, valued at 8 times. That gives about $13.6 billion of enterprise value, which is roughly 40% below today’s share price. Our central case assumes $1.90 billion in 2027, the beat and raise pattern continuing and the 2028 target staying on track, at 12 times. That gives about $22.8 billion, close to where the shares trade now. Our upside case assumes $2.0 billion with revenue per test recovering, at 15 times, which gives about $30 billion.

So the price requires roughly $1.9 billion of 2027 revenue at a multiple below Natera’s. The evidence supports that, but only modestly, because consensus is $1.84 billion. The gap we see sits in the mix of that revenue more than in the total. The price treats Shield revenue per test as flat. We think coverage pushes it up through 2027, and that shows up in gross profit before it shows up in revenue.

The next test is November 5. A result that would strengthen the thesis: Q3 Shield tests of 85,000 or more, screening revenue of $70 million or more, total revenue above $350.6 million, the 2026 guide raised above $1.36 billion and the Shield guide above 285,000. A result that would break it: Shield tests under 75,000, screening revenue per test under $700, the Shield guide cut below 270,000, or the revenue guide cut below $1.34 billion. A flat Q3 followed by fewer than 90,000 Shield tests in Q4 also breaks it.

What we are watching

• November 5, 2026, Q3 results. Strengthens: 85,000 or more Shield tests, $70 million or more of screening revenue, total revenue above $350.6 million and both guides raised. Breaks: fewer than 75,000 tests, revenue per test below $700, or either guide cut.
• November 5, 2026, the same call. Strengthens: management confirms UnitedHealth claims are being paid at a disclosed or implied rate at or above the blended $800. Breaks: commentary that commercial pricing is settling well below that level.
• November 15, 2026, Carelon coverage takes effect. Strengthens: no delays and covered lives confirmed near 90 million in later company updates. Breaks: any postponement or narrowing of the policy.
• Late January 2027, Abbott’s fourth quarter results. Strengthens: modest early SimpleScreen volumes. Breaks: Abbott reporting a launch big enough to match Shield’s early quarters.
• February 2027, Guardant’s Q4 results. Strengthens: Q4 Shield tests well above 90,000, revenue per test rising, and 2027 guidance above $1.84 billion. Breaks: Shield below 90,000 after a flat Q3, or a 2027 guide below consensus.

The bottom line

Blood screening for colorectal cancer was always going to be decided by payers rather than by sequencing machines. Guardant made a bet that looked expensive for most of 2026: run the tests before the plans paid, build the ordering habit, and trust coverage to follow. Coverage is now following, faster than we expected a year ago.

The price asks for the central case and little more, so the shares only need the plan to keep working. Abbott is a serious competitor, and we would rather own the company with the coverage, the reps and a funded balance sheet than the one starting from zero.

What would change our mind is simple. If Q3 and Q4 show Shield volume rising while revenue per test slides below $700, then coverage was not the constraint, Guardant has been buying growth, and we would walk away from this thesis without arguing with the numbers.

References

1. Guardant Health, Inc. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance. Form 8K Exhibit 99.1. US Securities and Exchange Commission. Published July 30, 2026. Accessed October 22, 2026. https://www.sec.gov/Archives/edgar/data/0001576280/000157628026000036/gh-06302026xexhibit991.htm
2. Guardant Health, Inc. Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening. Guardant Health Investor Relations. Published September 2026. Accessed October 22, 2026. https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Healths-Shield-Blood-Test-Covered-by-Carelon-Health-Services-for-Colorectal-Cancer-Screening/default.aspx
3. Investing.com. Earnings call transcript: Guardant Health tops Q2 2026 estimates as shares jump. Investing.com. Published July 30, 2026. Accessed October 22, 2026. https://www.investing.com/news/transcripts/earnings-call-transcript-guardant-health-tops-q2-2026-estimates-as-shares-jump-93CH-4826400
4. Guardant Health, Inc. Form 10Q for the quarterly period ended March 31, 2026. US Securities and Exchange Commission. Published May 2026. Accessed October 22, 2026. https://www.sec.gov/Archives/edgar/data/0001576280/000157628026000026/gh-20260331.htm
5. Guardant Health, Inc. Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026. Guardant Health Investor Relations. Published October 8, 2026. Accessed October 22, 2026. https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-to-Report-Third-Quarter-2026-Financial-Results-on-November-5-2026/default.aspx
6. MDDI Online. Freenome’s Blood Test for Colorectal Cancer Receives FDA Approval; Abbott to Commercialize. MDDI Online. Published July 2026. Accessed October 22, 2026. https://www.mddionline.com/ivd/freenome-s-blood-test-for-colorectal-cancer-receives-fda-approval-abbott-to-commercialize
7. MarketBeat. Guardant Health (GH) Q3 2026 Earnings Date, Time and Estimates. MarketBeat. Published October 2026. Accessed October 22, 2026. https://www.marketbeat.com/earnings/reports/2026-11-5-guardant-health-inc-stock/
8. Yahoo Finance. Guardant Health, Inc. (GH) Analyst Ratings, Estimates and Forecasts. Yahoo Finance. Published 2026. Accessed October 22, 2026. https://finance.yahoo.com/quote/GH/analysis/
9. Investing.com. Guardant Health earnings beat by $0.33, revenue topped estimates. Investing.com. Published July 30, 2026. Accessed October 22, 2026. https://www.investing.com/news/earnings/guardant-health-earnings-beat-by-033-revenue-topped-estimates-4826131
10. Finspry. Guardant Health, Inc. (GH) Forecast: Analyst Ratings and Targets. Finspry. Published October 8, 2026. Accessed October 22, 2026. https://finspry.com/stocks/gh/forecast
11. StockAnalysis. Natera (NTRA) Market Cap. StockAnalysis. Published October 2, 2026. Accessed October 22, 2026. https://stockanalysis.com/stocks/ntra/market-cap/
12. Natera, Inc. Natera Reports Second Quarter 2026 Financial Results. Form 8K Exhibit 99.1. US Securities and Exchange Commission. Published August 6, 2026. Accessed October 22, 2026. https://www.sec.gov/Archives/edgar/data/0001604821/000160482126000015/ntra-20260630xex991.htm

Not financial advice.